Acrivon Therapeutics, Inc. announced the appointment of Jean-Marie Cuillerot, M.D., as chief medical officer. Dr. Cuillerot was previously the chief medical officer at Dragonfly Therapeutics where he established and led a clinical team advancing multiple potential first-in-class assets. Prior to Dragonfly, Dr. Cuillerot was the chief medical officer of Agenus, where he led development activities for five investigational therapies.

At EMD Serono, an affiliate of Merck Serono, Dr. Cuillerot served as the global head of clinical development in immuno-oncology (IO) and as the vice president of clinical immunotherapy/IO. He oversaw the company's IO portfolio which included two checkpoint inhibitors and two immuno-cytokines. Notably, Dr. Cuillerot advanced avelumab, the first drug approved to treat Merkel cell carcinoma and second-line bladder cancer, from pre-IND through global submissions in record time, an achievement that earned him the Merck CEO Award.

From 2007 to 2012, he was at Bristol-Myers Squibb, where he served as the medical lead for the life cycle management of ipilimumab, an anti-CTLA-4 antibody and the world's first immune checkpoint therapy for cancer. Here he designed and led Phase 2 and Phase 3 studies across multiple indications and supported regulatory filings in the United States and Europe. Earlier in his career, Dr. Cuillerot also served in clinical development at Novartis, as a clinical research physician at the Centre d?Immunologie Pierre Fabre, and as an assistant professor at the Hôpitaux Universitaires de Strasbourg.

Dr. Cuillerot received a B.S. in biochemistry, an M.Sc. in cellular and molecular biology and an M.D. at the University Louis Pasteur (Strasbourg, France). The company announced that Erick Gamelin, M.D., Ph.D., has transitioned to the role of Chief Development Officer.

In this role, Dr. Gamelin will leverage his more than 30 years of broad translational and clinical expertise to continue to develop and support Acrivon?s overall research and development strategy, working closely with the preclinical and clinical development teams to prioritize and advance new pipeline programs and external opportunities.